Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder
OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But
cognitive cybersecurity intelligence
Subscribe to HEAL Security Dispatch for the latest healthcare cybersecurity news and analysis.
OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But
In a randomized pilot trial of 39 adults, researchers found that participants receiving medically tailored meals or Noom regained about 3.6% of their body weight
A study initiated by a University of Arizona Cancer Center physician-scientist Dr. Dan Theodorescu revealed that the loss of the Y chromosome in men’s body
When payors consider only the cost of the medication and not the cost and risk to the patient, doctor, and healthcare system, the irony is